Combined use of anti-ErbB monoclonal antibodies and erlotinib enhances antibody-dependent cellular cytotoxicity of wild-type erlotinib-sensitive NSCLC cell lines
Published 2012 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Combined use of anti-ErbB monoclonal antibodies and erlotinib enhances antibody-dependent cellular cytotoxicity of wild-type erlotinib-sensitive NSCLC cell lines
Authors
Keywords
-
Journal
Molecular Cancer
Volume 11, Issue 1, Pages 91
Publisher
Springer Nature
Online
2012-12-12
DOI
10.1186/1476-4598-11-91
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Phase I/II Trial of Cetuximab and Erlotinib in Patients with Lung Adenocarcinoma and Acquired Resistance to Erlotinib
- (2011) Y. Y. Janjigian et al. CLINICAL CANCER RESEARCH
- Lapatinib inhibits receptor phosphorylation and cell growth and enhances antibody-dependent cellular cytotoxicity of EGFR- and HER2-overexpressing esophageal cancer cell lines
- (2011) Kousaku Mimura et al. INTERNATIONAL JOURNAL OF CANCER
- EGFR Inhibitors Enhanced the Susceptibility to NK Cell-mediated Lysis of Lung Cancer Cells
- (2011) Hyunsu Kim et al. JOURNAL OF IMMUNOTHERAPY
- EGFR expression as a predictor of survival for first-line chemotherapy plus cetuximab in patients with advanced non-small-cell lung cancer: analysis of data from the phase 3 FLEX study
- (2011) Robert Pirker et al. LANCET ONCOLOGY
- Metabolism of the EGFR tyrosin kinase inhibitor gefitinib by cytochrome P450 1A1 enzyme in EGFR-wild type non small cell lung cancer cell lines
- (2011) Roberta R Alfieri et al. Molecular Cancer
- Treatment of Non–Small-Cell Lung Cancer with Erlotinib or Gefitinib
- (2011) Vince D. Cataldo et al. NEW ENGLAND JOURNAL OF MEDICINE
- Synergistic activity of letrozole and sorafenib on breast cancer cells
- (2010) Mara A. Bonelli et al. BREAST CANCER RESEARCH AND TREATMENT
- Cetuximab and First-Line Taxane/Carboplatin Chemotherapy in Advanced Non–Small-Cell Lung Cancer: Results of the Randomized Multicenter Phase III Trial BMS099
- (2010) Thomas J. Lynch et al. JOURNAL OF CLINICAL ONCOLOGY
- The Role of Human Epidermal Growth Factor Receptor 2 as a Prognostic Factor in Lung Cancer: A Meta-Analysis of Published Data
- (2010) Lingxiang Liu et al. Journal of Thoracic Oncology
- Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 study
- (2010) Federico Cappuzzo et al. LANCET ONCOLOGY
- Complement activation mediates cetuximab inhibition of non-small cell lung cancer tumor growth in vivo
- (2010) Yi-Fan Hsu et al. Molecular Cancer
- Everolimus restores gefitinib sensitivity in resistant non-small cell lung cancer cell lines
- (2009) Silvia La Monica et al. BIOCHEMICAL PHARMACOLOGY
- Molecular Predictors of Outcome With Gefitinib and Docetaxel in Previously Treated Non–Small-Cell Lung Cancer: Data From the Randomized Phase III INTEREST Trial
- (2009) Jean-Yves Douillard et al. JOURNAL OF CLINICAL ONCOLOGY
- Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial
- (2009) Robert Pirker et al. LANCET
- Mechanisms of Acquired Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancer
- (2008) J. A. Engelman et al. CLINICAL CANCER RESEARCH
- Combined lapatinib and cetuximab enhance cytotoxicity against gefitinib-resistant lung cancer cells
- (2008) H.-P. Kim et al. MOLECULAR CANCER THERAPEUTICS
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now